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Abstract
Background Parkinson’s disease (PD) is a progressive
neurodegenerative disorder of the central nervous system,
observed in patients aged older than 50 years. In this study,
we review interactions between therapies used in PD and
selected antihypertensive agents. Moreover, in view of the
lack of evidence-based recommendations regarding the
pharmacotherapy of arterial hypertension in PD patients,
we propose effective and safe therapeutic algorithms for
these two coexisting conditions.
Method We used the ‘‘Drug interactions’’ database affil-
iated with the Ministry of Health, which allows for the
identification of interactions between compared active
compounds. The database is updated on a monthly basis
and all data are consistent with current legislation. For
information about interactions, we additionally added data
from the British National Formulary, a joint publication of
the British Medical Association and the Royal Pharma-
ceutical Society of Great Britain. In this analysis, we also
used data from Micromedex, Cerner MultumTM, Wolters
KluwerTM, Lexicomp and Stockley’s. We analysed the
potential interactions between antihypertensive and anti-
parkinsonian agents included in respective guidelines on
the pharmacotherapy of these conditions.
Results Our analysis revealed the lack of clinically rele-
vant interactions between preparations of levodopa and
benserazide (used for the treatment of PD) and angiotensin-
converting enzyme inhibitors, antagonists of AT1 receptor
for angiotensin II or antagonists of b-adrenoreceptors (b-
adrenolytics).
Conclusion To avoid major drug-to-drug interactions,
patients receiving preparations of levodopa and bensera-
zide should be prescribed angiotensin-converting enzyme
inhibitors, antagonists of AT1 receptor for angiotensin II, or
antagonists of b-adrenoreceptors (b-adrenolytics) as the
first-line agents of antihypertensive treatment.
Key Points
We lack detailed guidelines on the pharmacotherapy
of arterial hypertension in patients with Parkinson’s
disease.
Pharmacotherapy of arterial hypertension in this
group should be individualised.
Angiotensin-converting enzyme inhibitors,
antagonists of AT1 receptor for angiotensin II or
antagonists of b-adrenoreceptors seem to be the
safest option of hypotensive treatment for patients
with Parkinson’s disease.
Introduction
Parkinson’s disease (PD) is a progressive neurodegenera-
tive disorder of the central nervous system, most frequently
observed in patients aged older than 50 years. The
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pathomechanism of PD is associated with the death of
dopamine-generating cells in the midbrain’s substantia
nigra. The concomitant degeneration of other neurons is
reflected by disorders in the cholinergic, noradrenergic and
serotoninergic systems. The death of approximately 80 %
of the dopamine-generating cells is reflected by an evident
loss of muscular control, which manifests as a slowness of
movement, balancing disorders, rigidity and spasticity of
muscles, and shaking of the limbs and head. Furthermore,
many patients experience orthostatic impairment of circu-
latory regulation at advanced stages of PD. Orthostatic
hypotension is the most frequent cardiovascular condition
associated with PD. It is usually defined as a drop in sys-
tolic blood pressure by at least 20 mm Hg during the initial
3 min of verticalisation [1–4].
Epidemiological data suggest that about 50 % of
patients with PD experience concomitant orthostatic
hypotension and arterial hypertension (especially in the
supine position). The signs of arterial hypertension and
orthostatic hypotension reduce the quality of life of patients
and represent an important therapeutic problem [5–9].
Antihypertensive agents can exacerbate the signs of
orthostatic hypotension or interact with drugs used in PD, thus
aggravating the symptoms of this condition. However,
untreated PD-related arterial hypertension can result in left
ventricular hypertrophy. Still, there is a lack of evidence-
based recommendations regarding the pharmacotherapy of
arterial hypertension in PD patients. Therefore, the choice of
antihypertensive agents in patients with co-existing PD
should be based on a 24-h profile of blood pressure, taking
into account the interactions between antihypertensive and
anti-parkinsonian agents. Often, improper pharmacotherapy
of arterial hypertension can enhance the signs of PD and as a
consequence decreasing the quality of a patient’s life [10–15].
Because of their clinical importance, drug-to-drug
interactions can be classified as major/significant (life
threatening), moderate (requiring additional interventions)
and minor/insignificant (without clinical consequences).
The knowledge of drug-to-drug interactions by clinicians is
vitally important as it enables them to predict potential
risks associated with prescription of a given agent. How-
ever, the effect of a given interaction and its severity may
differ significantly from patient to patient. Older individ-
uals constitute a particular risk group for drug-to-drug
interactions; this results mostly from the presence of
numerous comorbidities and age-related changes in phar-
macokinetics [16].
Aim of the Study
The aim of this study was to analyse the interactions
between selected anti-parkinsonian and antihypertensive
agents in view of international guidelines on the pharma-
cotherapy of these conditions [17–19]. Moreover, based on
this analysis, we aimed to develop recommendations
regarding effective and safe therapy of arterial hyperten-
sion coexisting with PD. We summarise the risks and
benefits of current treatments.
Method
We used the ‘‘Drug interactions’’ database affiliated with
the Ministry of Health, Poland, which allows for the
identification of interactions between compared active
compounds. The database was developed in cooperation
with researchers from the Faculty of Pharmacology, Col-
legium Medicum at Jagiellonian University in Cracow,
Poland. The database is updated on a monthly basis and all
data are consistent with current legislation. The programme
‘‘Drug interactions’’ allows the analysis of the potential
interactions between antihypertensive and anti-parkinso-
nian agents and the determination of the degree of the
clinical gravity of the drug–drug interactions (no interac-
tions, non-significant interactions, significant interactions,
very significant interactions).
For information about interactions, we added data from
the British National Formulary, a joint publication of the
British Medical Association and the Royal Pharmaceutical
Society of Great Britain. In this analysis, we also used data
from Micromedex, Cerner MultumTM, Wolters Klu-
werTM, Lexicomp and Stockley’s.
We analysed the potential interactions between antihy-
pertensive and anti-parkinsonian agents included in




Diuretics constitute a group of drugs that are inhomoge-
neous in terms of structure and target site within the
nephron. According to the American guidelines (JNC-7
2003), diuretics are recommended as the first-line group of
agents in the therapy of arterial hypertension. Diuretics can
be classified as thiazides and thiazide-like agents (chloro-
thiazide, hydrochlorothiazide, trichloromethiazide, ben-
droflumethiazide, chlorthalidone, indapamide), loop
diuretics (furosemide, etacrine acid, piretanide, torasemide)
and potassium-sparing diuretics (amiloride, spironolactone,
triamterene).
Owing to their mechanism of action, diuretics can be
divided into those acting in the proximal tubules
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(sulphonamide-acetazolamide), loop diuretics (chloroben-
zenesulfonamide and dichlorophenoxyacetic acid deriva-
tives), agents acting in the cortical part of the distal
convoluted tubules (thiazides and heterocyclic thiazides),
agents acting in the collecting ducts (aldosterone antago-
nists and agents acting independently of aldosterone),
xanthine diuretics and osmotic diuretics [20, 21].
Thiazides and Thiazide-like Agents
Diuretics, especially thiazide (hydrochlorothiazide) and
thiazide-like agents (chlorthalidone, indapamide), are the
most frequently used antihypertensive drugs. The mecha-
nism of their action is associated with blocking the
resorption of sodium ions (Na?) in the cortical part of the
ascending arm of the nephron loop and in the proximal part
of the distal tubule. Because they decrease urinary elimi-
nation of calcium, thiazides and thiazide-like diuretics can
contribute to hypercalcemia. Additionally, similarly to loop
diuretics, they increase urinary elimination of potassium
and increase blood concentration of uric acid (hyperurice-
mia) [22–24].
The effects of agents used in PD can be modified as a
result of both pharmacokinetic and pharmacodynamic
interactions. The interaction between hydrochlorothia-
zide and anti-parkinsonian agents, such as amantadine
and combination of levodopa with benserazide, is sig-
nificant. Concurrent administration of hydrochlorothia-
zide and amantadine can cause very significant drug–
drug pharmacokinetic interactions. This is reflected by a
marked increase in amantadine concentration, resulting
from the inhibition of the tubular secretion of this agent
by hydrochlorothiazide, and aggravation of its side
effects, such as nausea, sleeplessness, vertigo, problems
with concentration, orthostatic drop in blood pressure,
peripheral edema, memory loss, depression, seizure,
heart failure, ocular irritation, hypertension, changes in
blood morphology, psychoses, speech disorders, skin
hypersensitivity and photophobia. In such cases, a thi-
azide diuretic should be discontinued and the dose of
amantadine should be reduced or replaced with another
agent.
Concurrent administration of hydrochlorothiazide and
levodopa in combination with benserazide or hydrochlo-
rothiazide, chlorthalidone, indapamide and levodopa in
combination with benserazide and entacapone leads to
significant drug–drug pharmacokinetic interactions,
resulting in an enhanced hypotensive effect. This can be
associated with orthostatic hypotension.
Combination of bromocriptine or cabergoline with
hydrochlorothiazide leads to a non-significant interaction
associated with possible aggravation of the hypotensive
effect of the diuretic.
Concurrent use of indapamide and amantadine can be
reflected by significant interaction characterised by the
aggravation of the side effects of the anti-parkinsonian
agent. In such cases, the thiazide diuretic should be with-
drawn and the dose of amantadine should be reduced or
replaced with another agent.
Administration of indapamide along with levodopa in
combination with benserazide can significantly enhance the
hypotensive effect, which, similarly to interaction with
hydrochlorothiazide, leads to orthostatic hypotension.
Indapamide in combination with biperiden leads to
insignificant interaction associated with the stimulation of
the diuretic effect, resulting from its faster absorption from
the alimentary tract.
Data sources include Micromedex, updated May 6th,
2014, Cerner MultumTM, updated June 16th, 2014 and
Wolters KluwerTM, updated June 12th, 2014.
Table 1 presents the interactions between thiazide and
thiazide-like agents most frequently used in the treatment
of arterial hypertension and anti-parkinsonian agents,
stratified according to their significance.
Loop Diuretics
Loop diuretics (furosemide, etacrine acid, piretanide, to-
rasemide) exert stronger hypotensive effect than thiazide
diuretics. They act in the ascending part of the loop of
Henle. About 30 % of the glomerular load of Na? and Cl-
is absorbed in this part of the nephron, along with K?, and
large amounts of Ca2? and Mg2?. Loop diuretics inhibit
the Na?2–Cl–K? co-transporter, enabling the inflow of
Na? into the tubular cells. These agents show maximal
efficacy because up to 30 % of the glomerular load of Na?
is eliminated with urine as a result of their action. Trans-
location of large amounts of Na? and K? ions into the
distal parts of the nephron stimulates exchange of Na? to
H? or K?, potentially contributing to kaliuresis and
hypokalemia. Moreover, loop diuretics block resorption of
Ca2? and Mg2?, leading to enhanced urinary elimination of
these elements, and contribute to hyperuricemia owing to
enhanced renal resorption of uric acid [25, 26].
Significant interaction between furosemide and aman-
tadine, increasing the risk of QT segment prolongation and
a torsade de pointes (TdP) type of arrhythmia, should be
considered when choosing loop diuretics as antihyperten-
sive agents in individuals with PD. Amantadine and furo-
semide are both drugs with a conditional risk for TdP. This
means that the risk of developing TdP highly depends on
other risk factors for this condition (e.g. age, presence of
concomitant cardiovascular pathologies, potassium level
and renal function). Potassium supplementation can be
advised in the case of hypokalemia, but should be
accompanied by appropriate monitoring of the potassium
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level. Furthermore, amantadine should not be prescribed
concomitantly to drugs that prolong the QT interval. Fur-
thermore, this agent is known to escalate the effect of
neurostimulatory drugs, thus increasing the risk of neuro-
logical side effects (e.g. restlessness, nervousness and
sleeplessness) and arrhythmia. We used the ‘‘Drug inter-
actions’’ database affiliated with the Ministry of Health,
Poland. Such information was not given in Micromedex,
Cerner MultumTM and Wolters KluwerTM.
Administration of furosemide or torasemide along with
levodopa combined with benserazide or entacapone can
significantly enhance the hypotensive effect, which, simi-
larly to the interaction between hydrochlorothiazide and
indapamide, aggravates the orthostatic hypotension.
Table 2 presents the interactions between loop diuretics
most frequently used in the treatment of arterial hyper-
tension and anti-parkinsonian agents, stratified according to
their significance.
Potassium-Sparing Diuretics
Antikaliuretic diuretics act in the distal part of the nephron
(aldosterone antagonists and agents acting independently
from aldosterone). They block the sodium channels of
collecting tubules involved in the exchange of sodium ions
Na? and potassium ions K?, which are further eliminated
with urine. Spironolactone is a representative of this group
[27].
Significant interaction between spironolactone and
levodopa combined with benserazide or entacapone should
be considered before the administration of potassium-
sparing diuretics as antihypertensive agents in individuals
with co-existing PD. Such interaction can enhance hypo-
tensive effect, thus aggravating the orthostatic hypotension.
Data sources include Micromedex, updated May 6th,
2014, Cerner MultumTM, updated June 16th, 2014 and
Wolters KluwerTM, updated June 12th, 2014. It is note-
worthy that this interaction is not included in Lexicomp
and Stockley’s databases.
Table 3 presents the interactions between potassium-
sparing diuretics most frequently used in the treatment of
arterial hypertension and anti-parkinsonian agents, strati-
fied according to their significance.
Angiotensin-Converting Enzyme Inhibitors
According to the 2011 recommendations of the Polish
Society for Arterial Hypertension, angiotensin-converting
enzyme (ACE) inhibitors can be used in non-complicated
arterial hypertension. ACE inhibitors are competitive
inhibitors of ACE, which is involved in the transformation
of angiotensin I (inactive decapeptide) into angiotensin II.
Angiotensin II is one of the strongest endogenous vaso-
constrictive factors. Moreover, ACE inhibitors also inhibit
kininase II, an enzyme catalyzing degradation of bradyki-
nin and other strong vasodilating peptides. This is reflected
Table 1 The interactions
between thiazide and thiazide-
like agents most frequently used
in the treatment of arterial
hypertension and anti-
parkinsonian agents, stratified
according to their significance
COMT catechol-O-methyl
transferase, MAO-B monoamine
oxidase B, 1 No interactions, 2
non-significant interactions, 3
significant interactions, 4 very
significant interactions
Drugs Hydrochlorothiazide Chlorthalidone Indapamide
Levodopa preparations
Levodopa ? benserazide 3 1 3
Levodopa ? carbidopa 1 1 1
Levodopa ? carbidopa ? entacapone 3 3 3
Dopamine receptor agonists
Cabergoline 1 1 2
Pramipexole 1 1 1
Bromocriptine 1 1 1
Rotigotine 1 1 1
Ropinirole 1 1 1
Piribedil 1 1 1
MAO-B inhibitors
Selegiline 1 1 1
Rasagiline 1 1 1
Amantadine 4 1 3
Cholinolytic agents
Pridinol 1 1 1
Biperidene 1 1 2
COMT inhibitors
Tolcapon 1 1 1
Entacapone 1 1 1
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by increased concentration of bradykinin, which stimulates
b2 receptors, as a result increasing the release of nitrogen
oxide (NO) and vasoactive prostaglandins, such as pros-
taglandin E2 or prostacyclins [28–30].
Although ACE inhibitors are not involved in significant
interactions with anti-parkinsonian agents according to the
Polish ministerial database, Lexicomp and Stockley’s
databases include significant interactions between mono-
amine oxidase B (MAO-B) inhibitors and ACE inhibitors
(level C in Lexicomp and monitor level in Stockley’s).
Some drugs (captopril, enalapril, benazepril) cause insig-
nificant drug–drug pharmacokinetic interactions mani-
fested by enhanced hypotensive effect of ACE inhibitors,
when combined with bromocriptine and cabergoline. This
can be associated with orthostatic hypotension. Although
most patients tolerate therapy with ACE inhibitors well, the
administration of these agents can be associated with
adverse effects, such as orthostatic hypotension, dry cough,
hyperkalemia, acute renal failure, proteinuria and vasoac-
tive oedema [28–30].
Considering the fact that orthostatic hypotension is the
most frequent cardiovascular disorder associated with PD,
its occurrence as an adverse effect of ACE inhibitors is
undesirable. The signs of hypotonia associated with the use
of ACE inhibitors can result from the lack of vascular tone,
normally induced by angiotensin II. This is particularly
evident in individuals with high plasma activity of renin, in
particular following the administration of the initial dose
[28–30].
Table 4 presents the interactions between ACE inhibi-
tors most frequently used in the treatment of arterial
hypertension and anti-parkinsonian agents, stratified
according to their significance.
Antagonists of AT1 Receptor for Angiotensin II
The mechanism behind the hypotensive effect of antago-
nists of AT1 receptor for angiotensin II is associated with
the binding of the drug to AT1 receptor for angiotensin II
(AT II) in adrenal glands and smooth muscles of the blood
vessels. This prevents the vasoconstrictive effect of
angiotensin II and aldosterone release. Of note, the
Table 2 The interactions between loop diuretics most frequently
used in the treatment of arterial hypertension and anti-parkinsonian
agents, stratified according to their significance
Drugs Furosemide Torasemide
Levodopa preparations
Levodopa ? benserazide 3 3
Levodopa ? carbidopa 1 1


















COMT catechol-O-methyl transferase, MAO-B monoamine oxidase
B, 1 No interactions, 2 non-significant interactions, 3 significant
interactions, 4 very significant interactions
* No information in Micromedex, Cerner MultumTM and Wolters
KluwerTM
Table 3 The interactions between potassium-sparing diuretics most
frequently used in the treatment of arterial hypertension and anti-
parkinsonian agents, stratified according to their significance
Drugs Spironolactone
Levodopa preparations
Levodopa ? benserazide 3*
Levodopa ? carbidopa 1


















COMT catechol-O-methyl transferase, MAO-B monoamine oxidase
B, 1 No interactions, 2 non-significant interactions, 3 significant
interactions, 4 very significant interactions
* No information in Lexicomp and Stockley’s databases
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antagonists of AT1 receptor for angiotensin II do not
modulate the metabolism of bradykinin, noradrenalin and
substance P [31–34].
Data from the Polish ministerial database suggest that
the antagonists of AT1 receptor for angiotensin II do not
interact with anti-parkinsonian agents, apart from an
insignificant interaction between sartans and bromocriptine
or cabergoline, which is associated with the enhancement
of their hypotensive effect [31–34]. In contrast, Lexicomp
and Stockley’s include significant interactions between
MAO-B inhibitors and antagonists of AT1 receptor.
Table 5 presents the interactions between the antago-
nists of AT1 receptor for angiotensin II most frequently
used in the treatment of arterial hypertension and anti-
parkinsonian agents, stratified according to their
significance.
Calcium Channel Antagonists
Calcium channel antagonists constitute the most popular
group of antihypertensive agents. Three groups of drugs are
used most often: dihydropyridine derivatives (nifedipine,
amlodipine), phenylalkylamines (verapamil) and ben-
zothiazepines (diltiazem). These groups differ in terms of
their pharmacological properties and chemical structure.
The mechanism underlying the effects of calcium channel
antagonists pertains to blocking calcium channels, which
results in the inhibition of the intracellular inflow of Ca2?
ions. Free intracellular Ca2? ions regulate the tonus of
vascular smooth muscles. Therefore, the blockade of the
intracellular inflow of Ca2? is reflected by decreased vas-
cular tone, reduced peripheral resistance and subsequent
drop in blood pressure [35–38].
There are noteworthy interactions between nifedipine,
amlodipine, felodipine, isradipine, nitrendipine, verapamil
or diltiazem and anti-parkinsonian agents, such as bromo-
criptine, ropinirole or levodopa combined with bensera-
zide. Concurrent administration of the abovementioned
agents and levodopa combined with benserazide or ent-
acapone can lead to insignificant drug–drug interaction at
the pharmacokinetic phase. This can be reflected by the
impairment of synaptic transmission by calcium channel
antagonists and the weaker effect of levodopa and ben-
serazide. Moreover, the previously mentioned antihyper-
tensive agents can be involved in insignificant interactions
with bromocriptine, resulting in the enhanced hypotensive
effect. Combining nifedipine, nitrendipine, verapamil or
diltiazem with ropinirole is associated with the risk of
bradycardia, arrhythmia and excessive decrease in blood
pressure; this latter can be also a consequence of the
interaction between amlodipine or isradipine and ropini-
role. Nifedipine, amlodipine, felodipine, isradipine,
nitrendipine, verapamil and diltiazem can also insignifi-
cantly interact with cabergoline (with the exception of
Table 4 The interactions
between angiotensin-converting
enzyme inhibitors most
frequently used in the treatment
of arterial hypertension and
anti-parkinsonian agents,




oxidase B, 1 No interactions, 2
non-significant interactions, 3
significant interactions, 4 very
significant interactions
Drugs Captopril Enalapril Benazepril Lisinopril Ramipril Imidapril
Levodopa preparations
Levodopa ? benserazide 1 1 1 1 1 1
Levodopa ? carbidopa 1 1 1 1 1 1
Levodopa ? carbidopa
? entacapone
1 1 1 1 1 1
Dopamine receptor agonists
Cabergoline 2 2 2 2 1 1
Pramipexole 1 1 1 1 1 1
Bromocriptine 2 2 2 1 1 1
Rotigotine 1 1 1 1 1 1
Ropinirole 1 1 1 1 1 1
Piribedil 1 1 1 1 1 1
MAO-B inhibitors
Selegiline 1 1 1 1 1 1
Rasagiline 1 1 1 1 1 1
Amantadine 1 1 1 1 1 1
Cholinolytic agents
Pridinol 1 1 1 1 1 1
Biperidene 1 1 1 1 1 1
COMT inhibitors
Tolcapon 1 1 1 1 1 1
Entacapone 1 1 1 1 1 1
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verapamil, which shows a significant interaction), leading
to the enhancement of the hypotensive effect of these
agents. It should be noted that, contrary to the Polish
database, Lexicomp and Stockley’s databases include
significant interactions between MAO-B inhibitors and
calcium channel antagonists. Data from: Micromedex,
Cerner MultumTM and Wolters KluwerTM also include
significant interactions between MAO-B inhibitors and
calcium channel antagonists. For example, selegiline and
amlodipineine may have additive effects in lowering a
patient’s blood pressure.
Table 6 presents the interactions between calcium
channel antagonists most frequently used in the treatment
of arterial hypertension and anti-parkinsonian agents,
stratified according to their significance.
Antagonists of b-Adrenoreceptors (b-Adrenolytics)
Antagonists of b-adrenoreceptors bind selectively to b-
adrenergic receptors and cause competitive reversible
antagonism of b-adrenergic stimulation of various organs.
The mechanism of their action is variable and not com-
pletely understood as suggested by differences in the
effects of various drugs from this group.
b-Adrenolytic agents are classified into several cate-
gories; namely, non-selective and selective antagonists
of b-adrenoreceptors. Non-selective b-adrenolytics
causing competitive blockade of b1 and b2 receptors
with intrinsic sympathomimetic activity include nadolol,
propranolol, tymolol and sotalol, while the group of
agents without such activity encompasses pindolol,
carteolol, penbutolol, oxprenolol and alprenolol. Simi-
larly, there are selective b-adrenolytics with intrinsic
sympathomimetic activity, such as atenolol, bisoprolol,
metoprolol and betaxolol, or without such activity, e.g.
acebutolol. Moreover, there is a group of a- and b-
adrenolytics that act as peripheral vasodilators by
blocking a1-adrenergic receptor (labetalol, carvedilol,
bucindolol) [39–42].
Interactions between agents such as acebutolol, biso-
prolol, propranolol and metoprolol and such anti-parkin-
sonian agents as bromocriptine, selegiline or ropinirole
should be considered. Concurrent administration of the
abovementioned b-adrenolytics and selegiline is reflected
by very significant interaction associated with the risk of
bradycardia and potentially dangerous reversal of b-
receptor blockade.
Moreover, a significant interaction between such active
compounds as acebutolol, atenolol, bisoprolol, carvedilol,
metoprolol, nebivolol or pindolol and ropinirole can occur,
with subsequent risk of bradycardia, arrhythmia and
excessive drop in blood pressure. The abovementioned b-
adrenolytics also insignificantly interact with bromocrip-
tine and cabergoline (and also, in the case of carvedilol,
Table 5 The interactions
between the antagonists of AT1
receptor for angiotensin II most
frequently used in the treatment
of arterial hypertension and
anti-parkinsonian agents,




oxidase B, 1 No interactions, 2
non-significant interactions, 3
significant interactions, 4 very
significant interactions
* Lexicomp and Stockley’s
include significant interactions
between MAO-B inhibitors and
AT1 receptor
Drugs Eprosartan Irbesartan Losartan Telmisartan Valsartan
Levodopa preparations
Levodopa ? benserazide 1 1 1 1 1
Levodopa ? carbidopa 1 1 1 1 1
Levodopa ? carbidopa ? entacapone 1 1 1 1 1
Dopamine receptor agonists
Cabergoline 2 2 2 2 2
Pramipexole 1 1 1 1 1
Bromocriptine 2 2 2 2 2
Rotigotine 1 1 1 1 1
Ropinirole 1 1 1 1 1
Piribedil 1 1 1 1 1
MAO-B inhibitors
Selegiline 1* 1* 1* 1* 1*
Rasagiline 1* 1* 1* 1* 1*
Amantadine 1 1 1 1 1
Cholinolytic agents
Pridinol 1 1 1 1 1
Biperidene 1 1 1 1 1
COMT inhibitors
Tolcapon 1 1 1 1 1
Entacapone 1 1 1 1 1
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with biperiden), which can be reflected by the enhancement
of their hypotensive effect.
Data sources include Micromedex, updated May 6th,
2014, Cerner MultumTM, updated June 16th, 2014 and
Wolters KluwerTM, updated June 12th, 2014.
Table 7 presents the interactions between antagonists of
b-adrenoreceptors most frequently used in the treatment of
arterial hypertension and anti-parkinsonian agents, strati-
fied according to their significance.
Discussion
At present, we lack detailed guidelines regarding the
pharmacotherapy of arterial hypertension and the choice of
hypotensive agents for patients with PD. Pharmacotherapy
of arterial hypertension in individuals with PD has to be
individualised. Achieving the desired effect of hypotensive
agents and avoiding adverse effects associated with their
interaction with anti-parkinsonian agents constitute pre-
requisites of efficacious antihypertensive therapy [43–45].
To avoid potential adverse effects, pharmacotherapy of
arterial hypertension should begin with the lowest possible
dose of the antihypertensive agent. If the results are
unsatisfactory, the dose of the single agent should be
increased. If monotherapy is unsuccessful, a combination
of drugs, preferably originating from various classes and
characterised by different modes of action, is recom-
mended. Blood pressure in older patients should be
decreased gradually to reduce the incidence of adverse
events [46–48].
According to the international guidelines, in the cases
where monotherapy with a small dose of antihypertensive
agent is insufficient to reduce blood pressure, it should be
replaced with another agent at a low dose, its initial dose
should be increased or combined therapy should be
implemented.
Consideration of a patient’s preferences and potential
interactions with agents used in the treatment of comorbidi-
ties constitutes a prerequisite of successful therapy [46–48].
In view of existing guidelines and evidence of potential
interactions between antihypertensive and anti-
Table 6 The interactions between calcium channel antagonists most frequently used in the treatment of arterial hypertension and anti-
parkinsonian agents, stratified according to their significance
Drugs Nifedipine Amlodipine Felodipine Isradipine Lacidipine Nitrendipina Verapamil Diltiazem
Levodopa preparations
Levodopa ? benserazide 2 2 2 2 1 2 2 2
Levodopa ? carbidopa 1 1 1 1 1 1 1 1
Levodopa ? carbidopa
? entacapone
2 2 2 2 1 2 2 2
Dopamine receptor agonists
Cabergoline 2 2 2 2 1 2 3 2
Pramipexole 1 1 1 1 1 1 1 1
Bromocriptine 2 2 2 2 1 2 2 2
Rotigotine 1 1 1 1 1 1 1 1
Ropinirole 3 3 1 3 1 3 3 3
Piribedil 1 1 1 1 1 1 1 1
MAO-B inhibitors
Selegiline 1* 1* 1* 1* 1* 1* 1* 1*
Rasagiline 1* 1* 1* 1* 1* 1* 1* 1*
Amantadine 1 1 1 1 1 1 1 1
Cholinolytic agents
Pridinol 1 1 1 1 1 1 1 1
Biperidene 1 1 1 1 1 1 1 1
COMT inhibitors
Tolcapon 1 1 1 1 1 1 1 1
Entacapone 1 1 1 1 1 1 1 1
COMT catechol-O-methyl transferase, MAO-B monoamine oxidase B, 1 No interaction, 2 non-significant interactions, 3 significant interactions,
4 very significant interactions
* Lexicomp, Stockley’s, Micromedex, Cerner MultumTM, Wolters KluwerTM include significant interactions between MAO-B inhibitors and
calcium channel antagonists
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parkinsonian agents, individualised hypotensive therapy
comprising drugs currently used by the patient should be
proposed [43–45].
Because of the lack of interactions, patients in whom
preparations of levodopa and benserazide were imple-
mented owing to co-existing PD and arterial hypertension
should be prescribed ACE inhibitors, antagonists of AT1
receptor for angiotensin II or antagonists of b-adrenore-
ceptors (b-adrenolytics) as the first-line agents of antihy-
pertensive treatment.
Although most patients tolerate the therapy with ACE
inhibitors well, in the case of patients with PD, special
attention should be paid to the potential occurrence of
orthostatic hypotension, a potential adverse event. In such
an event, withdrawal of ACE inhibitors and replacement
with antagonists of AT1 receptor for angiotensin II or b-
adrenoreceptor antagonists should be considered.
The adverse effects of b-adrenoreceptor antagonists
result from their influence on the central nervous system
and include fatigue, headache, sleeping disorders, sleep-
lessness, ‘‘living dreams’’ and depression (rarer in the case
of hydrophilic b-adrenolytics). Moreover, b-adrenolytics
can cause or enhance impotence or loss of libido in some
patients. As this type of adverse events is also
characteristic for PD, discontinuation of b-adrenolytics is
recommended if evidence for the enhancement of their
severity is present.
However, it should be remembered that sudden with-
drawal of b-adrenolytics after long-term use can be
reflected by ‘‘withdrawal syndrome’’, presenting with
arrhythmia, arterial hypertension and exacerbation of
angina pectoris.
The results of previous clinical trials suggest that
antagonists of AT1 receptor for angiotensin II are charac-
terised by a lower incidence of adverse events; addition-
ally, their advantages include long-term hypotensive effect
and mild onset of action. Therefore, they seem to be the
most beneficial antihypertensive agents for individuals
with co-existing PD.
Patients receiving dopamine agonists can be prescribed
loop diuretics or potassium-sparing diuretics as antihyper-
tensive therapy because of the lack of interaction between
these two groups of drugs. In the case of other antihyper-
tensive agents, one should consider their potential inter-
actions with various dopamine agonists and determine
whether the patient is receiving combined anti-parkinso-
nian therapy, including drugs that could potentially interact
with those used to treat arterial hypertension.
Table 7 The interactions between antagonists of b-adrenoreceptors most frequently used in the treatment of arterial hypertension and anti-
parkinsonian agents, stratified according to their significance
Drugs Acebutolol Atenolol Bisoprolol Carvedilol Metoprolol Nebiwolol Pindolol Propranolol
Levodopa preparations
Levodopa ? benserazide 1 1 1 1 1 1 1 1
Levodopa ? carbidopa 1 1 1 1 1 1 1 1
Levodopa ? carbidopa ? entacapone 1 1 1 1 1 1 1 1
Dopamine receptor agonists
Cabergoline 2 2 2 2 2 2 2 2
Pramipexole 1 1 1 1 1 1 1 1
Bromocriptine 2 2 2 2 2 2 2 1
Rotigotine 1 1 1 1 1 1 1 1
Ropinirole 3 3 3 3 3 3 3 1
Piribedil 1 1 1 1 1 1 1 1
MAO-B inhibitors
Selegiline 4 1 4 1 4 1 1 4
Rasagiline 1 1 1 1 1 1 1 1
Amantadine 1 1 1 1 1 1 1 1
Cholinolytic agents
Pridinol 1 1 1 1 1 1 1 1
Biperidene 1 1 1 2 1 1 1 1
COMT inhibitors
Tolcapon 1 1 1 1 1 1 1 1
Entacapone 1 1 1 1 1 1 1 1
COMT catechol-O-methyl transferase, MAO-B monoamine oxidase B, 1 No interactions, 2 non-significant interactions, 3 significant interactions,
4 very significant interactions
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Dopamine agonists should not be prescribed to patients
with dementia, signs of psychosis or mental confusion.
Moreover, existing arrhythmia or its history, peripheral
circulatory disorders or orthostatic hypotension constitute
indications to use these agents with caution.
The dose of dopamine agonists should be increased
gradually and blood pressure should be measured on a
regular basis. Other groups of anti-parkinsonian agents
should be considered for individuals with co-existing
hypertension.
MAO-B inhibitors and catechol-O-methyl transferase
inhibitors can be safely combined with all antihypertensive
agents (the only exceptions include concurrent use of ace-
butolol, bisoprolol, propranolol, or metoprolol and selegiline).
Cholinolytic agents can be safely used with loop
diuretics, potassium-sparing diuretics, ACE inhibitors,
antagonists of AT1 receptor for angiotensin II and calcium
channel antagonists, as they do not interact with these
antihypertensive agents.
The occurrence of the interactions between various
groups of anti-parkinsonian agents and antihypertensive
drugs is summarised in Table 8.
Conclusion
At present, we lack detailed guidelines regarding the
pharmacotherapy of arterial hypertension and the choice of
hypotensive agents for patients with PD. Pharmacotherapy
of arterial hypertension in individuals with PD has to be
individualised. Achieving the desired effect of hypotensive
agents and avoiding adverse effects associated with their
interaction with anti-parkinsonian agents constitute pre-
requisites of efficacious antihypertensive therapy.
The differences between British, Polish, and American
databases are very interesting. We believe that this infor-
mation should be taken into account for the patient’s well-
being.
Clinicians working with patients with PD need to know
the significance of these interactions to properly advise
patients and prevent therapeutic problems.
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